<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39252826</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2475-0379</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Research and practice in thrombosis and haemostasis</Title><ISOAbbreviation>Res Pract Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.</ArticleTitle><Pagination><StartPage>102534</StartPage><MedlinePgn>102534</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102534</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rpth.2024.102534</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Early thromboprophylaxis does not prevent hospital admissions and death among outpatients with symptomatic COVID-19. Its impact on long-term outcomes, including long COVID symptoms and performance status, is unknown.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To assess the long-term effects of thromboprophylaxis given at the time of acute COVID-19 in outpatients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The OVID (enoxaparin for outpatients with COVID-19) trial randomized outpatients older than 50 years with acute COVID-19 to receive either subcutaneous enoxaparin 40 mg once daily for 14 days or standard of care (no thromboprophylaxis). In this follow-up study, we assessed the 2-year outcomes, including all-cause hospitalization and death, cardiovascular events, long COVID symptoms, and functional limitations based on the Post-COVID-19 Functional Status (PCFS) scale and EuroQol-5 Dimensions-5 Levels scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of 469 potentially eligible patients, 468 survived, of whom 439 (mean age 59 years; 54% men) participated in the Post-OVID study. There was no difference in terms of hospitalization and death (8.3% in the treatment group vs 10% in controls; relative risk, 0.83; 95% CI, 0.5-1.5) and of cardiovascular events between groups. The risk of presenting with long COVID symptoms was similar in the 2 groups (44% in the treatment group vs 47% in the standard of care group), with no difference between groups also concerning individual symptoms. A PCFS grade of 1 to 3, indicating light-to-moderate functional limitation, was recorded in 15% of patients in each group (odds ratio, 0.98; 95% CI, 0.6-1.7). No patients reported severe limitations (PCFS grade 4). Median EuroQol visual analog scale score was 85 on 100 points (IQR, 80-90 for the standard of care group and 75-90 for the enoxaparin group).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Early thromboprophylaxis does not improve long-term, 2-year clinical and functional outcomes among symptomatic ambulatory patients with acute COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fumagalli</LastName><ForeName>Riccardo M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voci</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bikdeli</LastName><ForeName>Behnood</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingisser</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emergency Department, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colucci</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service of Hematology, Clinica Luganese Moncucco, Lugano, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinica Sant'Anna, Sorengo, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forgo</LastName><ForeName>Gabor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grigorean</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klok</LastName><ForeName>Frederikus A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Righini</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert-Ebadi</LastName><ForeName>Helia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stortecky</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Inselspital Bern, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss</LastName><ForeName>D&#xf6;rte</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobohm</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kucher</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barco</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Angiology, University Hospital Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OVID investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Pract Thromb Haemost</MedlineTA><NlmUniqueID>101703775</NlmUniqueID><ISSNLinking>2475-0379</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Barco</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voci</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Held</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebastian</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bingisser</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colucci</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duerschmied</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frenk</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerber</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf6;tschi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konstantinides</LastName><ForeName>Stavros V</ForeName><Initials>SV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mach</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert-Ebadi</LastName><ForeName>Helia</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosemann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Noemi R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spechbach</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spirk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stortecky</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaisnora</LastName><ForeName>Lukas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Righini</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kucher</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zetzsche</LastName><ForeName>St&#xe9;phanie Roth</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spescha</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leeger</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butscheid</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Probst</LastName><ForeName>Eliane</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Micieli</LastName><ForeName>Evy</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forgo</LastName><ForeName>Gabor</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johner</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grigorean</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatsakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>Dagmar Keller</ForeName><Initials>DK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Speck</LastName><ForeName>Silvana Rampini</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasse</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rueegg</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nickel</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Busch</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blondon</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glauser</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cittone</LastName><ForeName>Micol G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kessler</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gjermeni</LastName><ForeName>Diona</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivier</LastName><ForeName>Christoph B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauchel</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biever</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobohm</LastName><ForeName>Lukas</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindewolf</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuenzi</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39252826</ArticleId><ArticleId IdType="pmc">PMC11381852</ArticleId><ArticleId IdType="doi">10.1016/j.rpth.2024.102534</ArticleId><ArticleId IdType="pii">S2475-0379(24)00229-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Hsu C.K., Yen M.Y., Lee P.I., Ko W.C., Hsueh P.R. Long COVID: an inevitable sequela of SARS-CoV-2 infection. J&#xa0;Microbiol Immunol Infect. 2023;56:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9576029</ArticleId><ArticleId IdType="pubmed">36283919</ArticleId></ArticleIdList></Reference><Reference><Citation>Cares-Marambio K., Montenegro-Jim&#xe9;nez Y., Torres-Castro R., Vera-Uribe R., Torralba Y., Alsina-Restoy X., et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021;18 doi: 10.1177/14799731211002240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14799731211002240</ArticleId><ArticleId IdType="pmc">PMC7975482</ArticleId><ArticleId IdType="pubmed">33729021</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A'Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananworanich J., Mogg R., Dunne M.W., Bassyouni M., David C.V., Gonzalez E., et al. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin Infect Dis. 2022;75:e473&#x2013;e481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522357</ArticleId><ArticleId IdType="pubmed">34523673</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Brooks M.M., Sciurba F.C., Krishnan J.A., Bledsoe J.R., Kindzelski A., et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326:1703&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S., Voci D., Held U., Sebastian T., Bingisser R., Colucci G., et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol. 2022;9:e585&#x2013;e593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243568</ArticleId><ArticleId IdType="pubmed">35779558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cools F., Virdone S., Sawhney J., Lopes R.D., Jacobson B., Arcelus J.I., et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol. 2022;9:e594&#x2013;e604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243570</ArticleId><ArticleId IdType="pubmed">35779560</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G., Spyropoulos A.C., Hsia J., Goldin M., Towner W.J., Go A.S., et al. Rivaroxaban for prevention of thrombotic events, hospitalization, and death in outpatients with COVID-19: a randomized clinical trial. Circulation. 2023;147:1891&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10270282</ArticleId><ArticleId IdType="pubmed">37154020</ArticleId></ArticleIdList></Reference><Reference><Citation>Avezum &#xc1;., Oliveira Junior H.A., Neves P.D.M.M., Alves L.B.O., Cavalcanti A.B., Rosa R.G., et al. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial. EClinicalMedicine. 2023;60 doi: 10.1016/j.eclinm.2023.102004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102004</ArticleId><ArticleId IdType="pmc">PMC10194052</ArticleId><ArticleId IdType="pubmed">37223666</ArticleId></ArticleIdList></Reference><Reference><Citation>Voci D., G&#xf6;tschi A., Held U., Bingisser R., Colucci G., Duerschmied D., et al. Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thromb Res. 2023;221:157&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9657896</ArticleId><ArticleId IdType="pubmed">36396519</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S., Bingisser R., Colucci G., Frenk A., Gerber B., Held U., et al. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:770. doi: 10.1186/s13063-020-04678-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04678-4</ArticleId><ArticleId IdType="pmc">PMC7479300</ArticleId><ArticleId IdType="pubmed">32907635</ArticleId></ArticleIdList></Reference><Reference><Citation>Human Research Act (HRA). https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;ved=2ahUKEwjC8qHgsPCHAxU4gP0HHaShAaQQFnoECC8QAQ&amp;url=https%3A%2F%2Fwww.swissmedic.ch%2Fdam%2Fswissmedic%2Fen%2Fdokumente%2Fbewilligungen%2Fklv%2Ffederal_act_on_researchinvolvinghumanbeingshumanresearchacthra.pdf.download.pdf%2Ffederal_act_on_researchinvolvinghumanbeingshumanresearchacthra.pdf&amp;usg=AOvVaw1ID40xYmjAtm3JISrmRo3A&amp;opi=89978449. [accessed February 1, 2024].</Citation></Reference><Reference><Citation>Devlin N., Pickard S., Busschbach J. In: Value sets for EQ-5D-5L: a compendium, comparative review &amp; user guide. Devlin N., Roudijk B., Ludwig K., editors. Springer; Cham (CH): 2022. The development of the EQ-5D-5L and its value sets; pp. 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">36810025</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin N.J., Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343080</ArticleId><ArticleId IdType="pubmed">28194657</ArticleId></ArticleIdList></Reference><Reference><Citation>Matter-Walstra K., Klingbiel D., Szucs T., Pestalozzi B.C., Schwenkglenks M. Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? Pharmacoeconomics. 2014;32:591&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">24671924</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Boon G.J.A.M., Barco S., Endres M., Geelhoed J.J.M., Knauss S., et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56 doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado F.V.C., Meys R., Delbressine J.M., Vaes A.W., Go&#xeb;rtz Y.M.J., van Herck M., et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health Qual Life Outcomes. 2021;19:40. doi: 10.1186/s12955-021-01691-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-021-01691-2</ArticleId><ArticleId IdType="pmc">PMC7856622</ArticleId><ArticleId IdType="pubmed">33536042</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong C.M.M., Boon G.J.A.M., Le Y.N.J., Barco S., Siegerink B., Klok F.A. The Post-Venous Thromboembolism Functional Status Scale: from call to action to application in research, extension to COVID-19 patients, and its use in clinical practice. Semin Thromb Hemost. 2023;49:764&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">36940713</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong C.M.M., Le Y.N.J., Boon G.J.A.M., Barco S., Klok F.A., Siegerink B. Eight lessons from 2 years of use of the Post-COVID-19 Functional Status scale. Eur Respir J. 2023;61 doi: 10.1183/13993003.00416-2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00416-2023</ArticleId><ArticleId IdType="pmc">PMC10151454</ArticleId><ArticleId IdType="pubmed">37080570</ArticleId></ArticleIdList></Reference><Reference><Citation>DescTools: Tools for descriptive statistics  R&#xa0;package version 0.99.23. 2017. http://cran.nexr.com/web/packages/DescTools/DescTools.pdf [accessed February 1, 2024].</Citation></Reference><Reference><Citation>Inspiration Investigators Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. Eur J Intern Med. 2022;103:76&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212871</ArticleId><ArticleId IdType="pubmed">35879217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Satapathy A.K., Bahinipati P. Delayed catastrophic thrombotic events in post-acute COVID-19. Thromb Res. 2022;220:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9550280</ArticleId><ArticleId IdType="pubmed">36270117</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems L.H., Nagy M., Ten Cate H., Spronk H.M.H., Groh L.A., Leentjens J., et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022;209:106&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642246</ArticleId><ArticleId IdType="pubmed">34922160</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight R., Walker V., Ip S., Cooper J.A., Bolton T., Keene S., et al. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146:892&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484653</ArticleId><ArticleId IdType="pubmed">36121907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J&#xa0;Infect Dis. 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J&#xa0;Med Virol. 2022;94:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetlevik &#xd8;., Wensaas K.A., Baste V., Emberland K.E., &#xd6;zg&#xfc;m&#xfc;s T., H&#xe5;berg S.E., et al. Prevalence and predictors of post-COVID-19 symptoms in general practice - a registry-based nationwide study. BMC Infect Dis. 2023;23:721. doi: 10.1186/s12879-023-08727-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08727-6</ArticleId><ArticleId IdType="pmc">PMC10599052</ArticleId><ArticleId IdType="pubmed">37880583</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  A&#xa0;clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. https://iris.who.int/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1 [accessed February 1, 2024].</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Author correction: long&#xa0;COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:408. doi: 10.1038/s41579-023-00896-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00896-0</ArticleId><ArticleId IdType="pmc">PMC10408714</ArticleId><ArticleId IdType="pubmed">37069455</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>